The eminent roles of ncRNAs in the pathogenesis of psoriasis.
Psoriasis
lncRNA
miRNA
Journal
Non-coding RNA research
ISSN: 2468-0540
Titre abrégé: Noncoding RNA Res
Pays: Netherlands
ID NLM: 101688191
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
20
06
2020
revised:
28
06
2020
accepted:
28
06
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
epublish
Résumé
Psoriasis is a chronic immune-related disorder in which both genetic and environmental parameters are involved. Recent studies have demonstrated dysregulation of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the peripheral blood or skin lesions of patients with psoriasis. While a number of lncRNAs such as MEG3, AL162231.4 and NONHSAT044111 have been down-regulated in the course of psoriasis, others including PRINS, MIR31HG, RP6-65G23.1, MSX2P1, SLC6A14-1:1, NR_003062 have been up-regulated. Moreover, expressions of several miRNAs have been dysregulated in this disorder. Among dysregulated miRNAs are miR-126, miR-143, miR-19a and miR-155 whose diagnostic roles in the psoriasis have also been assessed. Dysregulated non-coding RNAs in this disorder participate in the regulation of chemokine signaling pathway and immune response, control of epidermal development and skin barrier as well as modulation of function of certain subsets of T cells. Besides, these transcripts possibly regulate activity of NF-κΒ, mTOR, MAPK and JAK-STAT signaling pathways. Besides, expression levels of circRNAs have been decreased in the psoriasis lesions. Massive alterations in the levels of lncRNAs and miRNAs in the psoriasis lesions or peripheral blood of affected individuals show participation of these transcripts in the pathogenesis of this disorder.
Identifiants
pubmed: 32695942
doi: 10.1016/j.ncrna.2020.06.002
pii: S2468-0540(20)30050-0
pmc: PMC7355384
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
99-108Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 [The Author/The Authors].
Références
J Cell Physiol. 2019 Apr;234(4):3661-3674
pubmed: 30607907
Sci Transl Med. 2014 Feb 26;6(225):225re1
pubmed: 24574341
J Autoimmun. 2000 Feb;14(1):63-78
pubmed: 10648117
J Clin Lab Anal. 2018 Nov;32(9):e22588
pubmed: 29943471
J Invest Dermatol. 2011 Jul;131(7):1521-9
pubmed: 21412257
J Immunol. 2013 Jan 15;190(2):678-88
pubmed: 23233723
J Clin Invest. 2018 Jun 1;128(6):2551-2568
pubmed: 29757188
Exp Cell Res. 2018 Feb 15;363(2):243-254
pubmed: 29339075
Biomed Pharmacother. 2019 Jul;115:108761
pubmed: 31100542
J Invest Dermatol. 2017 Sep;137(9):1945-1954
pubmed: 28595995
Life Sci. 2019 Aug 1;230:28-34
pubmed: 31108094
Clin Immunol. 2014 Jan;150(1):22-30
pubmed: 24316592
Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3142-3152
pubmed: 28844950
Genome Biol. 2015 Jan 30;16:24
pubmed: 25723451
Int J Immunogenet. 2020 Feb 23;:
pubmed: 32090437
Biomed Rep. 2018 Nov;9(5):367-374
pubmed: 30402223
Biomed Pharmacother. 2017 Jun;90:524-530
pubmed: 28402921
Biol Res. 2018 Sep 4;51(1):30
pubmed: 30180891
Mol Med Rep. 2019 May;19(5):3421-3430
pubmed: 30816535
J Invest Dermatol. 2017 Oct;137(10):2177-2186
pubmed: 28642156
BMC Mol Cell Biol. 2019 Oct 28;20(1):46
pubmed: 31660855
J Cell Biochem. 2020 Feb 17;:
pubmed: 32065443
J Exp Med. 2004 Mar 1;199(5):731-6
pubmed: 14981113
Physiol Res. 2017 Dec 20;66(6):987-992
pubmed: 28937251
Biomed Pharmacother. 2018 Jul;103:1163-1169
pubmed: 29864894
Mol Cell Probes. 2020 Aug;52:101573
pubmed: 32325105
BMC Med Genomics. 2019 Nov 27;12(1):174
pubmed: 31775754
J Invest Dermatol. 2001 Nov;117(5):1296-301
pubmed: 11710947
Oxid Med Cell Longev. 2019 Dec 19;2019:8061901
pubmed: 31929856
Mol Genet Genomics. 2020 May;295(3):741-749
pubmed: 32125527
Eur J Dermatol. 2013 Sep-Oct;23(5):608-13
pubmed: 24135466
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Pol Merkur Lekarski. 2015 Mar;38(225):169-73
pubmed: 25815620
Cell Death Dis. 2018 May 11;9(5):567
pubmed: 29752469
Pathol Res Pract. 2017 Feb;213(2):89-97
pubmed: 28040329
Eur J Dermatol. 2012 Jan-Feb;22(1):68-71
pubmed: 22133505
Oncotarget. 2017 Apr 20;8(31):51288-51295
pubmed: 28881648
DNA Cell Biol. 2017 Mar;36(3):219-226
pubmed: 28085489
Eur J Dermatol. 2013 Nov-Dec;23(6):807-11
pubmed: 24192448
Br J Dermatol. 2011 Nov;165(5):1003-10
pubmed: 21711342
Eur J Pharmacol. 2019 Nov 5;862:172659
pubmed: 31518563
Nat Commun. 2015 Jul 03;6:7652
pubmed: 26138368
Curr Opin Pharmacol. 2009 Aug;9(4):514-20
pubmed: 19525145
Biomed Pharmacother. 2017 Sep;93:1158-1164
pubmed: 28738533
Int Immunopharmacol. 2020 Jan;78:106053
pubmed: 31812071
Cell Commun Signal. 2018 Sep 15;16(1):58
pubmed: 30219085
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):312-322
pubmed: 27535005
Br J Dermatol. 2019 Feb;180(2):365-372
pubmed: 30269330
Mol Med Rep. 2019 Jun;19(6):5227-5236
pubmed: 31059052
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491865
J Cell Mol Med. 2017 Feb;21(2):278-285
pubmed: 27641447
Exp Dermatol. 2010 Mar;19(3):269-78
pubmed: 20377629
Arch Dermatol Res. 1989;281(1):24-30
pubmed: 2525009
Immunol Lett. 2015 Jul;166(1):55-62
pubmed: 26045321
Noncoding RNA. 2019 Apr 19;5(2):
pubmed: 31010202